AbbVie Inc. (NYSE:ABBV) Surprised Investors; Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL) announced XIAFLEX


AbbVie Inc. (NYSE:ABBV) has announced new $5 billion stock buyback and also increased dividend. Company has authorized a new $5 billion stock buyback program and increased the company’s quarterly cash dividend by nearly 17 percent. The authorization allows for the repurchase of up to $5 billion of the company’s common stock, which is expected to be executed over the next several years. Furthermore, the board declared an increase in the company’s quarterly cash dividend from $0.42 per share to $0.49 per share, payable on Feb. 13, 2015 to stockholders of record as of Jan. 15, 2015. AbbVie Inc. (NYSE:ABBV) in last trading activity advanced 1.95% to close at $54.41. Company weekly performance is 1.47% while its quarterly performance stands at 1.42%. AbbVie Inc. (NYSE:ABBV) is -8.67% away from its 52 week high.

In another news AbbVie Inc. (NYSE:ABBV) announced cancellation of proposed AbbVie And Shire transaction. Abbvie (ABBV) to pay SHPG $1.635 billion breakup fee. Both companies have agreed to terminate their proposed merger following the decision by AbbVie’s Board to withdraw support for the proposed transaction. Abbvie’s decision was based upon its assessment of the September 22, 2014 notice issued by the U.S. Department of Treasury, which re-interpreted longstanding tax principles in a uniquely selective manner designed specifically to destroy the financial benefits of these types of transactions. The notice introduced an unacceptable level of risk and uncertainty given the magnitude of the proposed changes and the stated intention of the Department of Treasury to continue to revise tax principles to further impact such transactions.

Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL) announces XIAFLEX now approved for the concurrent treatment of up to two affected joints in the same hand in Dupuytren’s Contracture patients. Comapny announced that the FDA has approved a supplemental Biologics Application (sBLA) for XIAFLEX (collagenase clostridium histolyticum or CCH) for the treatment of up to two Dupuytren’s contracture (:DC) joints in the same hand during a single treatment visit. XIAFLEX is a biologic approved in the U.S., EU, Canada and Australia for the treatment of adult DC patients with a palpable cord. On last trading day Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL) fell -0.13% to close at $30.59. Its volatility for the week is 2.42% while volatility for the month is 2.34%. AUXL’s sales growth for past 5 years was 26.20% and its EPS growth for past 5 years was 19.90%. Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL) monthly performance is -1.77%.


Leave a Reply

Your email address will not be published. Required fields are marked *